NCT04602000 - A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection | Biotech Hunter

Enrollment

1,642

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

May 21, 2021

Study Completion Date

October 20, 2021

Conditions

SARS-CoV-2 Infection

Interventions

BIOLOGICAL

CT-P59

CT-P59 (40 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)

BIOLOGICAL

CT-P59

CT-P59 (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)

BIOLOGICAL

Placebo

Placebo (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)

BIOLOGICAL

CT-P59

CT-P59 (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)

BIOLOGICAL

Placebo

Placebo (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)

Trial Locations (1)

Chungnam National University Hospital, Daejeon